Provenance du réseau au premier degré de Laurenz Govaerts
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.
24
| Subsidiary | Investment Managers | 24 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Laurenz Govaerts via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
BMEYE BV
 BMEYE BV Electronic Equipment/InstrumentsElectronic Technology BMEYE BV operates as a non-invasive cardiovascular monitoring company. The firm manufactures and distributes non-invasive technology, hemodynamic monitoring equipment and related medical devices. It offers finger arterial pressure and cardiac output technologies. The company was founded in April 2005 and is headquartered in Amsterdam, the Netherlands. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member | |
| Coöperatief LSP IV UA | Investment Managers | Director/Board Member | |
| Imperial College London | College/University | Doctorate Degree | |
| École Polytechnique Fédérale de Lausanne | College/University | Graduate Degree | |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| McGill University | College/University | Undergraduate Degree | |
| University of Twente | College/University | Corporate Officer/Principal Graduate Degree | |
| NEXSTIM PLC | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
| University of Amsterdam | College/University | Undergraduate Degree Doctorate Degree | |
| Erasmus University Rotterdam | College/University | Graduate Degree Doctorate Degree Graduate Degree Doctorate Degree | |
| University of Leiden | College/University | Undergraduate Degree | |
| University of Utrecht | College/University | Doctorate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree | |
| Vrije Universiteit Amsterdam | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Doctorate Degree | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Chairman Director/Board Member | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
The Royal Netherlands Academy of Arts & Sciences
 The Royal Netherlands Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Netherlands Academy of Arts & Sciences provides research services in the field of science and art. The private company is based in Amsterdam, Netherlands and has subsidiaries in Netherlands. The CEO of the Dutch company is Wilma de Koning. | Miscellaneous Commercial Services | President Director/Board Member | |
| MERUS N.V. | Biotechnology | Director/Board Member | |
Polyganics BV
 Polyganics BV Medical SpecialtiesHealth Technology Polyganics BV engages in the development, manufacture, and commercialization of bioresorbable medical devices that facilitate tissue repair and regeneration. It offers pipeline, peripheral nerve repair, neurosurgery, and general surgery products . The company was founded in 1999 and is headquartered in Groningen, the Netherlands. | Medical Specialties | Chairman | |
Sequana Medical AG
 Sequana Medical AG Medical SpecialtiesHealth Technology Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland. | Medical Specialties | Chairman | |
| CELYAD ONCOLOGY SA | Biotechnology | Director/Board Member Corporate Officer/Principal | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member | |
Degroof Petercam Gestion
 Degroof Petercam Gestion Investment ManagersFinance Degroof Petercam Gestion (Degroof Gestion) is the French investment management subsidiary of Banque Degroof Petercam France SA, ultimately held by Banque Degroof Petercam SA (BSE: 698814) in Belgium. Formerly known as Aforge Gestion SAS, established in 2000, they became Degroof Petercam Gestion in 2015 and are located in Paris. | Investment Managers | Analyst-Equity | |
| Semaia Pharmaceuticals | Chief Executive Officer | ||
McKinsey & Co., Inc. (Belgium)
 McKinsey & Co., Inc. (Belgium) Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consultancy services. It serves businesses, governments, non governmental organizations, and non-profit organizations. The company was founded by James O. McKinsey in 1926 and is headquartered in Brussels, Belgium. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Neuravi Ltd.
 Neuravi Ltd. Medical SpecialtiesHealth Technology Neuravi Ltd. designs and develops medical devices for the treatment of acute stroke. Through its investment in the Neuravi Thromboembolic Initiative the company supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics to improve patient outcomes in stroke. Neuravi The company was founded by Mahmood K. Razav, Eamon Brady, John O'Shaughnessy and David Vale in 2009 and is headquartered in Galway, Ireland. | Medical Specialties | Director/Board Member Director/Board Member | |
LSP Advisory BV
 LSP Advisory BV Investment ManagersFinance Part of LSP Advisory Group BV, EQT Life Sciences is a healthcare investment firm based in Amsterdam, Netherlands. EQT Life Sciences has been connecting investors to inventors in the healthcare sector for over 30 years. The Dutch company has invested in close to two hundred private companies, raising billions of additional capital directed at supporting their R & D. EQT Life Sciences believes in fostering life and constant innovation in healthcare to achieve that goal. The company was founded in 1998, and Mark A. Wegter has been the CEO since then. Recently, EQT Life Sciences was acquired by EQT AB, one of the largest private equity firms in Europe, and among the top-ten private equity firms globally. | Investment Managers | Director/Board Member Chief Executive Officer | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
ViCentra BV
 ViCentra BV Electronic Equipment/InstrumentsElectronic Technology ViCentra BV engages in the development of medical devices. It focuses in creating devices for diabetes patients. The company was founded by Tim Oakes and Joseph John Cefai in 2013 and is headquartered in Utrecht, the Netherlands. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Onward Medical SA
 Onward Medical SA BiotechnologyHealth Technology ONWARD Inc develops medical devices. It also provides stimulation system to rehabilitate individuals with spinal cord injury. The company was founded by Jocelyn Bloch, Sjaak Deckers, Grégoire Courtine, and Vincent Delattre in December 2014 and is headquartered in Lausanne, Switzerland. | Biotechnology | Director/Board Member | |
Xylocor Therapeutics, Inc.
 Xylocor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Director/Board Member | |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Director/Board Member | |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member | |
| SEQUANA MEDICAL N.V. | Medical Specialties | Director/Board Member | |
Xilis, Inc.
 Xilis, Inc. Medical SpecialtiesHealth Technology Xilis, Inc. engages in the development of droplet-based microfluidics technology devices for precision cancer diagnostics and drug development. It offers Xilis platform. The company was founded by Xiling Shen and David Shu and is headquartered in Durham, NC. | Medical Specialties | Founder Director/Board Member | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member | |
Visus Therapeutics, Inc.
 Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
| ONWARD MEDICAL N.V. | Miscellaneous Commercial Services | Director/Board Member | |
Egle Therapeutics SAS
 Egle Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Egle Therapeutics SAS is a biotech company based in Paris, France. Egle Therapeutics develops first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases. The French company leverages its translational-based target discovery platform to unveil novel therapeutic Treg targets and computationally designed immunocytokines acting as antagonists or as selective Treg-agonists. The company was founded in 2020 by Luc Boblet, a serial biotech entrepreneur, and Dr. Eliane Piaggio, a renowned immunologist. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Consultant / Advisor Director of Finance/CFO Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Private Equity Investor Consultant / Advisor Private Equity Investor Private Equity Investor Consultant / Advisor General Counsel Consultant / Advisor | |
| InfectDetect | Chief Executive Officer | ||
Health Economics Privak II NV
 Health Economics Privak II NV Finance/Rental/LeasingFinance Health Economics Privak II NV is a Belgian company that provides credit intermediation services. The private company is based in De Pinte, Belgium. The company was founded in 2017. | Finance/Rental/Leasing | Director/Board Member Director/Board Member | |
| OCULIS HOLDING AG | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistiques
Internationale
| Pays-Bas | 23 |
| Belgique | 10 |
| Etats-Unis | 6 |
| Suisse | 6 |
| Royaume-Uni | 3 |
Sectorielle
| Health Technology | 26 |
| Consumer Services | 12 |
| Finance | 7 |
| Commercial Services | 5 |
| Electronic Technology | 3 |
Opérationnelle
| Director/Board Member | 138 |
| Private Equity Investor | 36 |
| Corporate Officer/Principal | 25 |
| Doctorate Degree | 18 |
| Independent Dir/Board Member | 14 |
Relations les plus connectées
| Insiders | |
|---|---|
| Martijn Kleijwegt | 33 |
| René Kuijten | 30 |
| Rudy Dekeyser | 29 |
| John Paul de Koning | 21 |
| Anne Portwich | 16 |
| Vincent Brichard | 15 |
| Hans Clevers | 14 |
| Bruno Luc Myriam Holthof | 14 |
| Clemens A. van Blitterswijk | 12 |
| Mark Wegter | 11 |
| Cillian King | 9 |
| Felice Verduyn-van Weegen | 9 |
| Geraldine O'Keeffe | 8 |
| Sonia Hallen | 8 |
| Philip Scheltens | 5 |
- Bourse
- Insiders
- Laurenz Govaerts
- Connexions Sociétés
